Beruflich Dokumente
Kultur Dokumente
Neuromyelitis optica (also known as Devics disease) is an idiopathic, severe, demyelinating disease of the central
nervous system that preferentially aects the optic nerve and spinal cord. Neuromyelitis optica has a worldwide
distribution, poor prognosis, and has long been thought of as a variant of multiple sclerosis; however, clinical,
laboratory, immunological, and pathological characteristics that distinguish it from multiple sclerosis are now
recognised. The presence of a highly specic serum autoantibody marker (NMO-IgG) further dierentiates
neuromyelitis optica from multiple sclerosis and has helped to dene a neuromyelitis optica spectrum of disorders.
NMO-IgG reacts with the water channel aquaporin 4. Data suggest that autoantibodies to aquaporin 4 derived from
peripheral B cells cause the activation of complement, inammatory demyelination, and necrosis that is seen in
neuromyelitis optica. The knowledge gained from further assessment of the exact role of NMO-IgG in the
pathogenesis of neuromyelitis optica will provide a foundation for rational therapeutic trials for this rapidly
disabling disease.
Introduction
Inammatory demyelinating diseases of the central
nervous system occur throughout the world and are the
foremost reason for non-traumatic neurological disability
in young, white adults;1 multiple sclerosis is the most
common of these disorders. The diagnosis of multiple
sclerosis requires conrmation that the symptoms and
signs of CNS white-matter involvement are disseminated
in time and space, supportive evidence from magnetic
resonance imaging and cerebrospinal uid analysis, if
needed, and the exclusion of other diagnoses (table).2
Multiple sclerosis is not associated with a specic
biomarker, and although intrathecal synthesis of
oligoclonal IgGs is characteristic of multiple sclerosis, no
target antigen has been dened;3 therefore, any relapsing
idiopathic demyelinating disease of the central nervous
system has, until recently, been diagnosed as multiple
sclerosis.4
Neuromyelitis optica (Devics disease) is an
inammatory, demyelinating syndrome of the central
nervous system that is characterised by severe attacks of
Multiple sclerosis
Neuromyelitis optica
Denition
85% remitting-relapsing
15% primary-progressive
Not monophasic
29
39
Sex (F:M)
2:1
9:1
Common
Rare
MRI: brain
Mild pleocytosis
Mononuclear cells
85%
1530%
805
Review
Epidemiology
Neuromyelitis optica is up to nine times more prevalent
in women than it is in men (table).5,16,34,35 The median age
http://neurology.thelancet.com Vol 6 September 2007
Review
Immunopathology
Demyelination in neuromyelitis optica extends across
multiple sections of the spinal cord, and the necrosis and
cavitation aect the grey matter and the white matter in
spinal cord and optic nerve lesions.33,59,60 Unlike in
multiple sclerosis, eosinophils and neutrophils are
commonly found in the inammatory inltrates of active
lesions of neuromyelitis optica,38,60 and the penetrating
spinal vessels are frequently thickened and hyalinised.33,60,61
Post-mortem studies conrm that brain lesions visualised
on MRI in neuromyelitis optica patients24 have the same
immunohistochemical characteristics as spinal cord
lesions.62,63
Immunoglobulin and complement components are
deposited in a characteristic vasculocentric rim and rosette
pattern in active neuromyelitis optica lesions (gure 2).60
Immune complexes are also deposited along myelin
sheaths and within macrophages in pattern II of the four
immunopathologically dened subsets of multiple
sclerosis.64 Active neuromyelitis optica lesions are distinctly
dierent because their vasculocentric distribution of
immune complexes corresponds to the normal expression
of aquaporin 4 in the endfeet of astrocytes.65,66 Similar
lesions are seen in east Asian optic-spinal multiple
807
Review
Review
LV
Ch pl
D
E
LV
Ch pl
B
F
3V
Ch pl
Figure 3: Brain lesions typical of neuromyelitis optica localise at the sites where aquaporin 4 expression are normally highest
Representative MRI of three patients who are seropositive for NMO-IgG. The images show lesions in periependymal regions of the brain; these sites are enriched with
aquaporin 4 (white dots on centre picture of midline sagittal section). In centre picture dashed black lines show the anatomical level of MRI in the diagram; arrows
show abnormality on uid-attenuated inversion recovery (FLAIR), T2-weighted signal or after being given gadolinium. Patient 1: image A (sagittal) and image B
(axial) have FLAIR signal abnormality around the 3rd ventricle, with extension into the hypothalamus. Patient 2 (image C; coronal, post-contrast T1-weighted image)
has subependymal enhancement along the frontal horns bilaterally and in the adjacent white matter. The immunouorescence photomicrograph linked to image C
shows the binding pattern of the serum IgG from a patient with neuromyelitis optica in a mouse brain (400X). Intense immunoreactivity of basolateral ependymal
cell membranes lining the lateral ventricle (LV) and extending into the subependymal astrocytic mesh coincides with aquaporin 4 immunoreactivity; the choroid
plexus (Ch pl) is unstained. Patient 3 has contiguous signal abnormality throughout the periventricular tissues: diencephalon (image D; axial T2-weighted), third
ventricle (image E; axial, FLAIR), and 4th ventricle (image F; axial FLAIR). Immunouorescence photomicrograph linked to image E shows the binding pattern of the
serum IgG from a patient with neuromyelitis optica in a mouse brain (400X), with intense staining of periventricular tissues (3rd ventricle, 3V); choroid plexus (Ch pl)
is unstained. Image C is courtesy of Allen Aksamit, Mayo Clinic College of Medicine.
Review
B
Monocyte
Blood
Activated
T
LFA-1
Monocyte
Blood
IgG pool
B
VLA-4
EOS
NMO-IgG
CD8
VCAM-1
ICAM-1
MHC II
CD4
Complement
activated
Monocyte
APC
TCR
CD8
Monocyte
AQP4
AQP4
EOS
AQP4
MS
antigen(s)
CNS
parenchyma
CD8
MMP-9
CNS
parenchyma
Astrocyte
foot
process
Clonal expansion
Demyelination
and axonal
injury
B
Vascular
hyalinisation
Complement
activated
CSF
MAC
CD4
CSF
Demyelination
and axonal
injury
Necrosis
MAC
EOS
N
OCB
Figure 4: Comparative immunopathological hypotheses for multiple sclerosis and neuromyelitis optica
In multiple sclerosis (panel A), peripherally activated T lymphocytes interact with endothelial cells, as an early event that leads to CNS inammation and clinical
exacerbations. Tethering and rolling of T lymphocytes along the endothelium results in binding of the 4 integrins (LFA-1, VLA-4) with their endothelial receptors
(VCAM-1, ICAM-1 [blue arrows]) and selectins (not shown), which initiates endothelial adhesion extravasation into the CNS parenchyma (cell movement is shown by
red arrows). Migration across the bloodbrain barrier is increased by release of proteinases such as MMP-9. CD4-positive T cells are reactivated after interaction of
their T-cell receptor with an unknown antigen presented in the CNS by class II major histocompatibility class (MHC) molecules on antigen-presenting cells (APC). The
intraparenchymal secretion of cytokines and chemokines leads to chemoattraction of other circulating leucocytes, including B lymphocytes (B), monocytes, and
CD8-positive T lymphocytes. The proinammatory cascade that results leads to demyelination and axonal injury through divergent mechanisms, including cytotoxic
CD8-positive T lymphocytes and macrophages (M). Clonal proliferation of inltrating B lymphocytes results in local antibody production which might augment
complement activation and axonal injury. Analysis of CSF from patients with multiple sclerosis typically detects small concentrations of lymphocytes and oligoclonal
IgG products. In neuromyelitis optica (panel B), the immunising event is not known; however, the peripheral immunoglobulin pool (blue) contains NMO-IgG (red).
These immunoglobulins have limited access to the CNS parenchyma, either through endothelial transcytosis or at areas of relative bloodbrain barrier permeability or
injury. The astrocytic foot processthe astrocyte terminus that is one constituent of the bloodbrain barrierwhich is bound to the basal lamina of the endothelium
makes the extracellular domain of aquaporin 4 channels accessible to any NMO-IgG entering this region. Increased permeability of the bloodbrain barrier caused by
complement activation would explain the massive inltration of leucocytes, including polymorphonuclear cells (eosinophils [EOS] and neutrophils [N]), detected in
the CSF in large numbers in the acute phase of neuromyelitis optica. The combined complement-mediated injury and cellular inux causes demyelination, severe
neuronal injury, and necrosis. Cytolytic injury by assembly of the membrane attack complex (MAC) of complement explains the irregular thickening and hyalinisation
of penetrating vessels in neuromyelitis optica lesions. Clonal expansion of B cells in the CNS is presumably uncommon, as indicated by the low prevalence of
oligoclonal IgG bands in CSF. Abbreviations: LFA-1=lymphocyte function-associated antigen 1; VLA-4=very late activation antigen 4; VCAM-1=vascular cell adhesion
molecule 1; ICAM-1=intercellular adhesion molecule 1; MMP-9=matrix metalloproteinase 9; TCR=T-cell receptor; AQP4=aquaporin 4.
Review
Brain involvement
Non-specic cerebral lesions seen with MRI are common
at the onset of neuromyelitis optica. Furthermore, new
brain lesions that are non-specic for neuromyelitis
optica develop in 60% of patients after the diagnosis of
neuromyelitis optica, and the immunohistopathological
characteristics of the brain lesions in these patients are
typical of those seen in the spinal cord of patients with
neuromyelitis optica.5,24,65,73,83 Over time, brain lesions that
meet MRI criteria for multiple sclerosis develop in
10% of patients who otherwise full the criteria for the
diagnosis of neuromyelitis optica.24,89 Another 10% of
patients have white-matter lesions in the periependymal
regions that are enriched in aquaporin 4, including the
hypothalamus and the periaqueductal brainstem
(gure 3).24,73,83,84 The white-matter lesions are sometimes
symptomatic and specic for neuromyelitis optica, and
could plausibly account for the non-autoimmune
endocrinopathies reported in association with
neuromyelitis optica.45,90 In contrast to studies of patients
http://neurology.thelancet.com Vol 6 September 2007
Review
Treatment
Intravenous corticosteroid therapy is commonly the
initial treatment for acute attacks of optic neuritis or
myelitis. Patients who did not respond promptly to
corticosteroid treatment beneted from seven treatments
of plasmapheresis (10 to 15 plasma volume per
exchange) over a period of 2 weeks in a randomised,
controlled, crossover trial of patients with acute, severe
demyelinating disease, which included patients with
neuromyelitis optica and acute transverse myelitis.110 In a
recent observational series of 6 patients with neuromyelitis
optica, a similar (50%) clinical response rate was reported
when plasmapheresis was used to treat patients with
attacks that were refractory to corticosteroid treatment.111
Early initiation of plasmapheresis is recommended,
particularly for patients with neuromyelitis optica with
severe cervical myelitis, who are at high risk for
neurogenic respiratory failure.5,112 Plasmapheresis is also
benecial for patients with acute, severe vision loss who
have optic neuritis that is refractory to corticosteroid
therapy.113
No controlled therapeutic trials have specically
investigated neuromyelitis optica.114 Until recently, most
patients with neuromyelitis optica were diagnosed with
progressive severe multiple sclerosis and treated with
immunomodulatory therapies that are approved for
reducing the frequency of relapse in multiple sclerosis
(eg, interferon beta and glatiramer acetate). However
clinical observations do not support the ecacy of these
drugs for treatment of neuromyelitis optica.114116
Maintenance immunosuppressive therapy is a generally
accepted strategy for reducing relapses of neuromyelitis
812
Conclusion
The heterogeneity of idiopathic inammatory
demyelinating diseases of the central nervous system is
one of the main factors that confound epidemiological,
genetic, and therapeutic studies of multiple sclerosis.
Neuromyelitis optica is a homogeneous disorder that can
be identied from within this group of demyelinating
diseases by a combination of clinical, neuroimaging,
serological, and pathological characteristics.120 The use of
these characteristics to distinguish neuromyelitis optica
from multiple sclerosis has considerable implications for
clinical practice and is important for preserving the
validity of therapeutic trials for multiple sclerosis by not
enrolling patients with neuromyelitis optica.
An eector role of NMO-IgG in the pathogenesis of
neuromyelitis optica has not yet been proven. Nevertheless,
the discovery of this antibody and its new class of
autoantigen is a valuable tool to dene an extended
spectrum of neuromyelitis-optica-related disorders.
Research must now investigate the potential pathogenicity
of NMO-IgG, the role of aquaporin 4 as the inducer and
target of this autoimmune attack, and the design of
treatment trials on the basis of detailed knowledge of the
pathogenesis of neuromyelitis optica. Two questions
about neuromyelitis optica that were posed by Eugne
Devic at the end of the 19th century are now closer to
being answered: Why such a peculiar localisation? and
What is the intimate nature of the process?13
Contributors
DMW selected most references, determined the structure of the review,
prepared the initial draft of the review, and designed gures 1 and 4. All
authors participated in revising the manuscript, suggested additional
references, and took principal responsibility for revisions and
corrections of sections in their major areas of expertise. VAL compiled
the section on immunobiological features of NMO-IgG and aquaporin 4,
Review
20
Conicts of interest
The authors disclose that, in accordance with the BayhDole Act of 1980
and Mayo Foundation policy, VAL, BGW, and CFL stand to receive
royalties for commercial assays to detect of aquaporin 4-specic
autoantibodies. The intellectual property is licensed to a commercial
entity for the development of a simple, antigen-specic assay, to be made
available worldwide for patient care. The test will not be exclusive to
Mayo Clinic. Until now, the authors have received less than $10 000 in
royalties. Mayo Clinic oers the test as an indirect immunouorescence
assay to aid the diagnosis of neuromyelitis optica but the authors do not
benet personally from the performance of the test. DMW has received
consulting fees from Genentech, and research or educational grant
support to Mayo Clinic from Berlex, Biogen Idec, Genentech, Genzyme
Pharmaceuticals, GlaxoSmithKline, Merck, Serono, and Teva
Neurosciences. BW has received consulting fees from Genentech and
grant support to Mayo Clinic from Berlex, Genzyme Pharmaceuticals,
and Serono. SJP has no conict of interest.
22
Acknowledgements
VAL wishes to acknowledge the assistance of Shannon Hinson and grant
support from the Ralph Wilson Medical Research Foundation.
References
1
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG.
Multiple sclerosis. N Engl J Med 2000; 343: 93852.
2
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for
multiple sclerosis: 2005 revisions to the McDonald Criteria.
Ann Neurol 2005; 58: 84046.
3
Frohman EM, Racke MK, Raine CS. Multiple sclerosisthe plaque
and its pathogenesis. N Engl J Med 2006; 354: 94255.
4
Kantarci OH, Weinshenker BG. Natural history of multiple
sclerosis. Neurol Clin 2005; 23: 1738.
5
Wingerchuk DM, Hogancamp WF, OBrien PC, Weinshenker BG.
The clinical course of neuromyelitis optica (Devics syndrome).
Neurology 1999; 53: 110714.
6
Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica.
Semin Neurol 2002; 22: 10522.
7
de Seze J. Neuromyelitis optica. Arch Neurol 2003; 60: 133638.
8
Weinshenker BG. Neuromyelitis optica: what it is and what it might
be. Lancet 2003; 361: 88990.
9
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF,
Weinshenker BG. Revised diagnostic criteria for neuromyelitis
optica. Neurology 2006; 66: 148589.
10 Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum
autoantibody marker of neuromyelitis optica: distinction from
multiple sclerosis. Lancet 2004; 364: 210612.
11 Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG
marker of optic-spinal multiple sclerosis binds to the aquaporin 4
water channel. J Exp Med 2005; 202: 47377.
12 Amiry-Moghaddam M, Ottersen OP. The molecular basis of water
transport in the brain. Nat Rev Neurosci 2003; 4: 9911001.
13 Devic E. Mylite aigu complique de nvrite optique. Bull Med
(Paris) 1894; 8: 103334.
14 Gault F. De la neuromylite optique aigu. Lyon; 1894.
15 Scolding N. Devics disease and autoantibodies. Lancet Neurol 2005;
4: 13637.
16 ORiordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and
MRI ndings in Devics neuromyelitis optica.
J Neurol Neurosurg Psychiatry 1996; 60: 38287.
17 Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical
predictors of a relapsing course and survival. Neurology 2003;
60: 84853.
18 Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable
hiccup and nausea with periaqueductal lesions in neuromyelitis
optica. Neurology 2005; 65: 147982.
19 Pittock SJ, Weinshenker BG, Wijdicks EF. Mechanical ventilation
and tracheostomy in multiple sclerosis.
J Neurol Neurosurg Psychiatry 2004; 75: 133133.
21
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
Howard RS, Wiles CM, Hirsch NP, Loh L, Spencer GT, NewsomDavis J. Respiratory involvement in multiple sclerosis. Brain 1992;
115: 47994.
Kurtzke JF. Cinical manifestations of multiple sclerosis. In: Vinken
PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam:
North-Holland; 1970: 161216.
de Seze J, Stojkovic T, Ferriby D, et al. Devics neuromyelitis optica:
clinical, laboratory, MRI and outcome prole. J Neurol Sci 2002;
197: 5761.
Chalumeau-Lemoine L, Chretien F, Gaelle Si Larbi A, et al. Devic
disease with brainstem lesions. Arch Neurol 2006; 63: 59193.
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF,
Weinshenker BG. Brain abnormalities in neuromyelitis optica.
Arch Neurol 2006; 63: 39096.
Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M, et
al. Optic neuromyelitis syndrome in Brazilian patients.
J Neurol Neurosurg Psychiatry 2002; 73: 42935.
Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in
recently diagnosed MS patients: added value of spinal MRI
examination. Neurology 2004; 62: 22633.
Mandler RN, Ahmed W, Denco JE. Devics neuromyelitis optica: a
prospective study of seven patients treated with prednisone and
azathioprine. Neurology 1998; 51: 121920.
Milano E, Di Sapio A, Malucchi S, et al. Neuromyelitis optica:
importance of cerebrospinal uid examination during relapse.
Neurol Sci 2003; 24: 13033.
McDonald WI, Compston A, Edan G, et al. Recommended
diagnostic criteria for multiple sclerosis: guidelines from the
International Panel on the diagnosis of multiple sclerosis.
Ann Neurol 2001; 50: 12127.
Ebers GC, Paty DW. CSF electrophoresis in one thousand patients.
Can J Neurol Sci 1980; 7: 27580.
McLean BN, Luxton RW, Thompson EJ. A study of
immunoglobulin G in the cerebrospinal uid of 1007 patients with
suspected neurological disease using isoelectric focusing and the
Log IgG-index: a comparison and diagnostic applications.
Brain 1990; 113 : 126989.
Bergamaschi R, Tonietti S, Franciotta D, et al. Oligoclonal bands in
Devics neuromyelitis optica and multiple sclerosis: dierences in
repeated cerebrospinal uid examinations. Mult Scler 2004; 10: 24.
Mandler RN, Davis LE, Jeery DR, Kornfeld M. Devics
neuromyelitis optica: a clinicopathological study of 8 patients.
Ann Neurol 1993; 34: 16268.
de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P.
Is Devics neuromyelitis optica a separate disease? A comparative
study with multiple sclerosis. Mult Scler 2003; 9: 52125.
Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical
characteristics, course and prognosis of relapsing Devics
neuromyelitis optica. J Neurol 2004; 251: 4752.
Barbieri F, Buscaino GA. Neuromyelitis optica in the elderly.
Acta Neurol 1989; 11: 24751.
Davis R, Thiele E, Barnes P, Riviello JJ Jr. Neuromyelitis optica in
childhood: case report with sequential MRI ndings.
J Child Neurol 1996; 11: 16467.
Mirsattari SM, Johnston JB, McKenna R, et al. Aboriginals with
multiple sclerosis: HLA types and predominance of neuromyelitis
optica. Neurology 2001; 56: 31723.
Osuntokun BO. The pattern of neurological illness in tropical
Africa. Experience at Ibadan, Nigeria. J Neurol Sci 1971; 12: 41742.
Cosnett JE. Multiple sclerosis and neuromyelitis optica. Case report
and speculation. S Afr Med J 1981; 60: 24951.
Modi G, Mochan A, Modi M, Saer D. Demyelinating disorder of
the central nervous system occurring in black South Africans.
J Neurol Neurosurg Psychiatry 2001; 70: 50005.
Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African
Americans. Arch Neurol 1998; 55: 18692.
Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of
African Americans vs Caucasian Americans with multiple sclerosis.
Neurology 2004; 63: 203945.
Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in
Martinique (French West Indies). Neurology 2001; 56: 50714.
Vernant JC, Cabre P, Smadja D, et al. Recurrent optic neuromyelitis
with endocrinopathies: a new syndrome. Neurology 1997; 48: 5864.
813
Review
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
814
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
Review
98
99
100
101
102
103
104
105
106
107
108
109
815